Category: 108258-54-4

Related Products of 108258-54-4, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.108258-54-4, Name is Methyl 2,3-dichloroquinoxaline-6-carboxylate, molecular formula is C10H6Cl2N2O2. In a Article£¬once mentioned of 108258-54-4

Synthesis and Fungicidal Activity of 1,4-Dithiino[2,3-b]quinoxaline-2,3-dicarbonitriles

A series of eleven 1,4-dithiino[2,3-b]quinoxaline-2,3-dicarbonitriles was prepared by reaction of 2,3-dichloroquinoxalines with disodium (Z)-2,3-dimercapto-2-butenedinitrile in N,N-dimethylformamide. These products were tested for in-vitro fungicidal activity by a Minimum Inhibitory Concentration (MIC) method. Several of these compounds showed broad-spectrum fungicidal activity. The activity exhibited by these compounds was greatly dependent upon the substituents of the quinoxaline ring, with the nitro-substituted derivatives showing the higest levels of antifungal activity. None of the compounds prepared, however, showed fungicidal activity comparable to that of the commercial fungicides screened.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 108258-54-4

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1988 | ChemSpider

Reference of 108258-54-4, Chemistry is the science of change. But why do chemical reactions take place? Why do chemicals react with each other? The answer is in thermodynamics and kinetics.In a document type is Patent, and a compound is mentioned, 108258-54-4, Methyl 2,3-dichloroquinoxaline-6-carboxylate, introducing its new discovery.

Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient

Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune diseases, containing the same as an active ingredient.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Reference of 108258-54-4. In my other articles, you can also check out more blogs about 108258-54-4

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1982 | ChemSpider

Related Products of 108258-54-4, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.108258-54-4, Name is Methyl 2,3-dichloroquinoxaline-6-carboxylate, molecular formula is C10H6Cl2N2O2. In a Patent£¬once mentioned of 108258-54-4

Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines

The present invention provides compounds of formula (I) 1 the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1, and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 108258-54-4

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1985 | ChemSpider

Electric Literature of 108258-54-4, Because a catalyst decreases the height of the energy barrier, its presence increases the reaction rates of both the forward and the reverse reactions by the same amount.108258-54-4, Name is Methyl 2,3-dichloroquinoxaline-6-carboxylate, molecular formula is C10H6Cl2N2O2. In a article£¬once mentioned of 108258-54-4

FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY

The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “”Fused Tricyclic Compounds””), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson”s disease.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 108258-54-4

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1986 | ChemSpider

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Computed Properties of C10H6Cl2N2O2, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 108258-54-4, name is Methyl 2,3-dichloroquinoxaline-6-carboxylate. In an article£¬Which mentioned a new discovery about 108258-54-4

Monoacylglycerol Lipase Modulators

Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 108258-54-4, help many people in the next few years.Computed Properties of C10H6Cl2N2O2

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1983 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108258-54-4,Methyl 2,3-dichloroquinoxaline-6-carboxylate,as a common compound, the synthetic route is as follows.

Step C hydrazine monohydrate (0.26 ML) was added dropwise to a suspension of 2,3-dichloro-quinoxaline-6-carboxylic acid methyl ester (1.2 g) in methanol (10 ML) at -10 C. After three hrs. at this temperature, an additional portion of hydrazine monohydrate (0.26 ML) was added, and the resulting mixture was stirred at 0 C. for three hrs., and then for one hr. at 23 C. The suspension was filtered, and the solids were washed with MeOH. Flash column chromatography provided a residue that was recrystallized from MeOH to provide 3-chloro-2-hydrazino-quinoxaline-6-carboxylic acid methyl ester as a yellow solid. MS (M+H)+=253.2.

108258-54-4, The synthetic route of 108258-54-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Pfizer Inc.; US2004/192698; (2004); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider